Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities - 10/07/23
Doi : 10.1016/j.jinf.2023.05.012
Yating Dian 1, Yu Meng 1
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, China
Furong Laboratory, Changsha, Hunan 410008, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
Yuming Sun
Department of Plastic and Cosmetic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
Guangtong Deng
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, China
Furong Laboratory, Changsha, Hunan 410008, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
Furong Zeng ⁎ 
Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
∗Correspondence to: Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.Department of Oncology, Xiangya Hospital, Central South UniversityChangshaHunanChina
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Patients with COVID-19 and pre-existing comorbidities are common. |
• | Azvudine is more effective than Paxlovid for COVID-19 patients. |
• | Azvudine is recommended for COVID-19 patients with pre-existing comorbidities. |
Plan
© 2023
The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 87 - N° 2
P. e24-e27 - août 2023 Retour au numéro
Article précédent
- Comment on ‘Neurosyphilis among people with and without HIV infection: A Danish nationwide prospective, population-based cohort study 2015–2021’
- Aleksander Kwaśny, Michał Pastuszak, Monika Czarnowska-Cubała, Julia Kwaśna
- Virulence factor genes and antimicrobial susceptibility of Staphylococcus lugdunensis strains
- Anna Budzyńska, Natalia Wiktorczyk-Kapischke, Katarzyna Grudlewska-Buda, Patrycja Erdmańska, Katarzyna Boczkowska, Ewa Wałecka-Zacharska, Eugenia Gospodarek-Komkowska, Krzysztof Skowron
Bienvenue sur EM-consulte, la référence des professionnels de santé.